- Anatara Lifesciences (ANR) enters into a trading halt while it plans a capital raise
- The company has not yet announced how much it plans to raise nor how it will spend the money
- The specialist life sciences company expects to remain in the trading halt until Friday, October 21, by which time it plans to have released the details of the capital raise
- Shares in Anatara last traded at 4.6 cents on October 17
Anatara Lifesciences (ANR) has entered a trading halt while it plans a capital raise.
The company has not yet announced how much it plans to raise nor how it will spend the money.
The specialist life sciences company expects to remain in the trading halt until Friday, October 21, by which time it plans to have released the details of the capital raise.
In May, the company received ethics approval to expand eligibility criteria for its irritable bowel syndrome (IBS) and psychological functioning trials.
The expansion came after the company was facing a significant screening failure rate due to the strict eligibility criteria.
With the approval, eligibility was able to expand to include all IBS subtypes allowing for 300 potential participants who previously were not able to enrol in the trial due to not having diarrhoea predominant IBS.
Shares in Anatara last traded at 4.6 cents on October 17.